XML 64 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Securities (Narrative) (Details)
12 Months Ended
Dec. 31, 2024
USD ($)
security
Dec. 31, 2023
USD ($)
security
Dec. 31, 2022
USD ($)
Marketable Securities [Line Items]      
Number of securities past due or on nonaccrual 0 0  
Securities evaluated for other than temporary impairment 123    
Available-for-sale Securities Pledged as Collateral | $ $ 50,178,000 $ 43,092,000  
Available for sale securities in an unrealized loss position for credit related impairment | $ 0 0  
Debt securities, available-for-sale, allowance for credit Loss | $ 0 0  
Allowance for credit losses on held-to-maturity securities | $ 0 0 $ 0
Proceeds from sale of securities available-for-sale | $ $ 31,353,000    
Publicly Traded Domestic Corporations [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 13    
U.S. Agency Obligations [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 56    
Municipals [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 54    
Reportable Legal Entities [Member]      
Marketable Securities [Line Items]      
Debt Securities, Available-for-Sale, Realized Loss | $ $ 41,000 0  
Debt Securities, Held-to-Maturity, Sale | $ 31,353,000 0  
Net gain from sale of available-for-sale securities | $ $ 103,000 $ 0  
Non-rated [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 6    
S&P Rated AAA [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 28    
S&P Rated AA [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 83    
S&P Rated A [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 3    
S&P Rated BBB [Member]      
Marketable Securities [Line Items]      
Securities evaluated for other than temporary impairment 3